Found: 15
Select item for more details and to access through your institution.
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
- Published in:
- Scientific Reports, 2015, p. 17499, doi. 10.1038/srep17499
- By:
- Publication type:
- Article
Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 22, p. 16085, doi. 10.3390/ijms242216085
- By:
- Publication type:
- Article
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
- Published in:
- 2015
- By:
- Publication type:
- Case Study
HER3 as a Therapeutic Target in Cancer.
- Published in:
- BioDrugs, 2017, v. 31, n. 1, p. 63, doi. 10.1007/s40259-016-0205-2
- By:
- Publication type:
- Article
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience.
- Published in:
- Diagnostics (2075-4418), 2024, v. 14, n. 10, p. 1024, doi. 10.3390/diagnostics14101024
- By:
- Publication type:
- Article
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma.
- Published in:
- Pulmonary Therapy, 2016, v. 2, n. 1, p. 1, doi. 10.1007/s41030-016-0013-3
- By:
- Publication type:
- Article
Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer.
- Published in:
- Journal of Oncology, 2019, p. 1, doi. 10.1155/2019/7475364
- By:
- Publication type:
- Article
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
- Published in:
- 2023
- By:
- Publication type:
- Product Review
Targeting RET-rearranged non-small-cell lung cancer: future prospects.
- Published in:
- Lung Cancer: Targets & Therapy, 2019, v. 10, p. 27, doi. 10.2147/LCTT.S192830
- By:
- Publication type:
- Article
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients.
- Published in:
- Cancers, 2024, v. 16, n. 3, p. 592, doi. 10.3390/cancers16030592
- By:
- Publication type:
- Article
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 4, p. 1047, doi. 10.3390/jcm9041047
- By:
- Publication type:
- Article
The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer.
- Published in:
- Life (2075-1729), 2023, v. 13, n. 9, p. 1915, doi. 10.3390/life13091915
- By:
- Publication type:
- Article
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.672219
- By:
- Publication type:
- Article
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
- Published in:
- Cell Communication & Signaling, 2019, v. 17, n. 1, p. N.PAG, doi. 10.1186/s12964-019-0446-z
- By:
- Publication type:
- Article